The primary objective of this phase 2 study is to investigate the therapeutic potential of orally administered combined delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in relieving both pain and cue-induced opioid craving in people with co-occurring opioid use disorder (OUD) and chronic pain who are undergoing methadone therapy.
Phase:
PHASE2
Details
Lead Sponsor:
Yale University
Collaborators:
National Institute on Drug Abuse (NIDA) National Institutes of Health (NIH)